Trial Profile
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Bronchial cancer; Cancer; Gastrointestinal cancer; Pancreatic cancer
- Focus Therapeutic Use
- 15 Mar 2023 Status changed from active, no longer recruiting to completed.
- 04 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Results of retrospective analysis in a single referral center (n=17) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.